Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Treatment of early stage adenocarcinoma

Choosing Wisely: Value added cancer care for India

15 - 16 Oct 2019

Published: 20 Feb 2020

Views: 1909

Rating:

Save

Dr C S Pramesh - Tata Memorial Hospital, Mumbai, India

Prof C S Pramesh presents a talk on 'Treatment of early stage adenocarcinoma' at the Choosing wisely: Value Added Cancer Care for India event in New Delhi.

Related Videos

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Time toxicity: the burden on cancer patients

Dr Arjun Gupta - University of Minnesota, Minneapolis, USA

Time toxicity: the burden on cancer patients ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

To avoid unnecessary second surgery in differentiated thyroid cancer

Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia

To avoid unnecessary second surgery in differentiated thyroid cancer ( Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia )

More from ecancer